Headlines about GlycoMimetics (NASDAQ:GLYC) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlycoMimetics earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.9617609093313 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of GlycoMimetics (GLYC) traded up $0.78 during trading hours on Friday, hitting $20.81. The stock had a trading volume of 546,900 shares, compared to its average volume of 543,487. GlycoMimetics has a 52-week low of $3.82 and a 52-week high of $21.40. The company has a market capitalization of $649.67, a PE ratio of -16.78 and a beta of 3.21.
GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.04. research analysts predict that GlycoMimetics will post -1.12 earnings per share for the current fiscal year.
In other news, SVP Helen M. Thackray sold 2,000 shares of the stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $15.01, for a total transaction of $30,020.00. Following the completion of the sale, the senior vice president now directly owns 148,615 shares in the company, valued at $2,230,711.15. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 43.80% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “GlycoMimetics (GLYC) Receives Media Impact Rating of 0.23” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2018/01/12/glycomimetics-glyc-receives-media-impact-rating-of-0-23.html.
GlycoMimetics Company Profile
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.